Eli Lilly and Company (LLY)vsNektar Therapeutics (NKTR)
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
NKTR
Nektar Therapeutics
$85.04
+2.21%
HEALTHCARE · Cap: $2.76B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 117909% more annual revenue ($65.18B vs $55.23M). LLY leads profitability with a 31.7% profit margin vs -297.1%. NKTR appears more attractively valued with a PEG of 0.31. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
NKTR
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Trading at 19.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -217.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : NKTR
The strongest argument for NKTR centers on PEG Ratio. PEG of 0.31 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : NKTR
The primary concerns for NKTR are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while NKTR is a turnaround play — different risk/reward profiles.
NKTR carries more volatility with a beta of 1.18 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 28/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Nektar Therapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?